Please login to the form below
Britain
This page shows the latest Britain news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca’s heart failure treatment approved for expanded use in EU
As well as this most recent EU approval, Forixga has also been approved in Great Britain, Japan and Turkey to extend the HF indication to include patients across the full spectrum
Latest news
-
BeiGene’s Brukinsa granted two new marketing authorisations by MHRA
Dr Renata Walewska, Department of Haematology, University Hospitals Dorset said: “The authorisation of Brukinsa for MZL and CLL in Great Britain is a significant step forward for eligible patients and their
-
Pfizer completes acquisition of Global Blood Therapeutics for $5.4bn
older. The drug is also approved in the EU, the UAE, Oman and Britain.
-
AstraZeneca’s Tezspire receives MHRA approval as add-on treatment for severe asthma
Tezspire demonstrated reduced annualised rate of asthma exacerbations. AstraZeneca’s (AZ) Tezspire (tezepelumab) has been granted marketing authorisation in Great Britain by the Medicines and Healthcare products Regulatory Agency (MHRA) for
-
Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
The marketing authorisation in Britain is specifically for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with ... Locametz (gozetotide)
-
Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn
The drug was approved in the US in November 2019 and is also approved in the EU, the UAE, Oman and Britain.
More from news
Approximately 3 fully matching, plus 257 partially matching documents found.
Latest Intelligence
-
Setting up for success in a post-Brexit, post-pandemic Britain
Creating a new biotech affiliate and seeking marketing authorisation for a new drug in the UK during a pandemic
-
Route 66: can remote working put two-thirds of us back on the road to engaged employment?
With a recent PwC poll showing that more than 20 of Britain’s biggest firms have no plans for employees to come back to the office, the need to evolve employee
-
Pharma funding and M&A in 2020
So in 2020, as much as investors will be paying attention to noises from Boston, the San Francisco Bay Area, Britain, yes Britain, and even Brussels, I suspect they’ll also
-
The transatlantic opioid crisis
Meanwhile, in Britain. A Public Health England enquiry revealed the scale of opioid consumption in the UK in September 2019, with prescriptions now being handed out to one in eight of
-
25 Women Leaders in UK Healthcare (part 2)
She became Britain’s youngest hospital leader when she was appointed chief executive of Birmingham Children’s Hospital in 2007 at the age of 32, subsequently helping it win Provider Trust
More from intelligence
Approximately 0 fully matching, plus 23 partially matching documents found.
Latest appointments
-
UCB appoints new managing director of Britain and Ireland
Steve Turley joins from Lundbeck
-
Gopa Mitra retires from PAGB
She steps down after 34 years at organisation. Gopa Mitra is to retire from the Proprietary Association of Great Britain (PAGB) after 34 years at the organisation.
-
GSK's Lawson elected PAGB president
The Proprietary Association of Great Britain (PAGB), which represents OTC companies in the UK, has elected Carlton Lawson of GlaxoSmithKline (GSK) as its new president.
-
MHRA announces senior appointment
McGuire's career has also seen him involved with a number of professional bodies, including the Association of Anaesthetists of Great Britain and Ireland, the Royal College of Anaesthetists and the
-
Steve Arnold joins UCB from Gilead
Appointed managing director for the British and Irish Isles. UCB has appointed Steve Arnold as managing director for Great Britain and Ireland.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
A new 10-year cancer plan: Will the government be able to deliver what the sector needs?
Britain has a strong track record of setting out plans for cancer services, with the most recent substantive strategy published in 2015 (Achieving world-class cancer outcomes: a strategy for England
-
IWD2021: #ChooseToChallenge Interview with Dennis O’Brien, Lucid Group CEO
I learnt so much from Melanie Lee, who was Director of R&D at Celltech, Britain’s most successful biotech.
-
Let's be ambitious for patients and life sciences investment in Global Britain
In post-Brexit ‘Global Britain’, Government wants a rejuvenated MHRA to help the UK become a global early launch market. ... sciences investment for the new Global Britain.
-
HOW INNOVATION IS RESHAPING THE NORTH EAST LIFE SCIENCES LANDSCAPE
In a post Brexit Britain where the UK’s future trading relationship with the EU remains uncertain, adopting more innovative business practices will be crucial to keeping the sector globally competitive. ... We must ensure the North East’s
-
The fight against COVID-19 needs to have diversity at the heart of its strategy
In recognition of this, the #CharitySoWhite campaign has demanded action over the disproportionate impact of the virus on Britain’s minorities.
More from PMHub
Approximately 0 fully matching, plus 24 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- LEO Pharma enters clinical trial partnership with ICON
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- How to create content for health professionals
- Sanofi to cut US insulin prices by up to 78% in January 2024
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- 2023 PM Society Awards – winners announced
- Next congress, please: making the most of virtual pharmaceutical congresses
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- Locus Biosciences announces first patient treated in urinary tract infection trial
- A relentless commitment to neuroscience
- AstraZeneca announces major expansion of Canadian research footprint
- BMS will not launch cancer drug Opdualag in Germany due to pricing pressures
- Regeneron’s application for Eylea in retinopathy of prematurity accepted for FDA priority review
- Neurodiversity and healthcare communications – do we know enough and do we do enough?
Latest intelligence
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
- THE EVOLVING ROLE OF PROCUREMENT?
- Procurement is evolving to reinforce its position as a strategic enabler of company growth. How can agency partners organisations to realise this?...
